A Phase I, Randomized, Dose-Ranging, Pharmacokinetic, Glucodynamic, Safety, and Tolerability Study of SC Administered Humulin R and Humalog With or Without Recombinant Human Hyaluronidase (rHuPH20) in Healthy Volunteers.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 May 2012
At a glance
- Drugs Hyaluronidase; Insulin; Insulin lispro
- Indications Diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Halozyme Therapeutics
- 30 May 2012 Planned end date changed from 1 Dec 2009 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 11 Dec 2009 Planned end date changed from 1 Oct 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
- 29 Sep 2009 Results will be presented at the 2009 International Diabetes Federation Congress and the Diabetes Technology Society meeting according to a Halozyme Therapeutics media release.